Beijing Hotgen Biotech Co., Ltd.
688068.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.84B
Close$
$3.20
96.1% downside
Current Fair Value
96.1% downsideOvervalued by 96.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.84 Billion |
|---|---|
| Enterprise Value | $7.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.24 |
| Beta | 0.39 |
| Outstanding Shares | 97,092,777 |
Return
| Return on Equity | -10.57% |
|---|---|
| Return on Assets | -8.43% |
| Return on Invested Capital | -12.53% |
Valuation & Multiples
| P/E Ratio | -32.77 |
|---|---|
| PEG | 1023 |
| Price to Sales | 20.34 |
| Price to Book Ratio | 3.13 |
| Enterprise Value to Revenue | 16.27 |
| Enterprise Value to EBIT | -21.09 |
| Enterprise Value to Net Income | -30 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Beijing Hotgen Biotech Co., Ltd.
946 employees
CEO: Changqing Lin Beijing Hotgen Biotech Co., Ltd. specializes in the complete process, from research and development to manufacturing and sales, of in-vitro diagnostic (IVD) solutions for medical and public safety purposes within the biomedical field. Th...